Alternatively, he can produce risk assessments of specific companies and products already of interest to investors.

To do this, Professor Oxford will look into:

• the quality of the research and development already invested in the over-the-counter remedy, vaccine or anti-viral drug
• expected regulatory approval time-frames
• platform technology potential
• similar drugs already in the market place; how that might affect consumer demand
• track record of the company involved
• clinical trial results